Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Leuzzi

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Biorxiv : the Preprint Server for Biology|February 27, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.
Molecular Cell|October 7, 2022
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomasYinglu Li, Elizabeth M Goldberg, Xiao Chen, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
CRISPRmap: Sequencing-free optical pooled screens mapping multi-omic phenotypes in cells and tissueJiacheng Gu, Abhishek Iyer, Ben Wesley, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Mapping the genetic landscape of the DNA damage response with Cas12a-based combinatorial knockout screensSamuel B Hayward, Alina Vaitsiankova, Tomas Lama-Diaz, et al.
Nature Biotechnology|October 7, 2024
Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmapJiacheng Gu, Abhishek Iyer, Ben Wesley, et al.
Cell|February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasionGiuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Biorxiv : the Preprint Server for Biology|February 27, 2026
SMARCAL1 is a candidate therapeutic target for ALT-positive tumorsAngelo Taglialatela, Jina Lee, Benura Azeroglu, et al.
Molecular Cell|October 7, 2022
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomasYinglu Li, Elizabeth M Goldberg, Xiao Chen, et al.
Biorxiv : the Preprint Server for Biology|January 18, 2024
CRISPRmap: Sequencing-free optical pooled screens mapping multi-omic phenotypes in cells and tissueJiacheng Gu, Abhishek Iyer, Ben Wesley, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Mapping the genetic landscape of the DNA damage response with Cas12a-based combinatorial knockout screensSamuel B Hayward, Alina Vaitsiankova, Tomas Lama-Diaz, et al.
Nature Biotechnology|October 7, 2024
Mapping multimodal phenotypes to perturbations in cells and tissue with CRISPRmapJiacheng Gu, Abhishek Iyer, Ben Wesley, et al.
Cell|February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasionGiuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Pageof 3